Competitive Technologies, Inc. (NYSE Amex:CTT) offers a non-invasive pain therapy without the harmful side effects of narcotic painkillers. Cleared for use in the U.S. by the Food and Drug Administration (FDA), the device offers a non-invasive method without harmful side effects for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. CTT's pain therapy also has Medical Device CE certification from the European Union.

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has obtained a commitment to purchase shares of its 5% Series B convertible preferred stock pursuant to a registered direct offering to a single institutional investor, representing gross proceeds of approximately $1.36 million. Twenty-five percent, or approximately $340,250, of the gross proceeds will be placed in an escrow account, which amounts will be released to make the dividend and other payments described below.

Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI - News), a commercial-stage biotechnology company with a focus in oncology, today announced that it has received commitments from institutional investors to purchase $21 million of securities in a registered direct offering. Spectrum expects to receive net proceeds of approximately $20 million after deducting placement agent fees and other offering expenses.

Skystar Bio-Pharmaceutical Co., Ltd. (NASDAQ:SKBI), a China-based producer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that it has priced its public offering of 1,400,000 shares of common stock. Skystar has granted the representative of the underwriters a 45-day option to purchase up to an additional 210,000 shares of common stock. The shares were offered to the public at $12.98 per share. The offering is expected to settle and close on July 7, 2009, subject to customary closing conditions.

By Ben Purvis, Gizmag.com

Entrepreneur behind the Segway developing eco hybrid that will run on anything that burns

Dean Kamen – the multimillionaire inventor behind the Segway personal transporter – is well down the road in the development of a new bike that combines electric power and a radical generator which will allow it to burn almost any fuel.

It is a medical mystery why approaches such as extracorporeal ozone therapy or even photopheresis seem to have therapeutic effects in certain situations. One possibility is that stressing of cells outside of the body causes formation of apoptotic bodies, with the apoptotic bodies having a therapeutic effect.

Source: insciences.org

Insight could lead to new therapies to repair damage caused by MS.

Scientists have discovered a new mechanism in brain stem cells that controls how and when they develop into cells which repair damage in neurological diseases such as multiple sclerosis (MS). They have found that a signalling pathway (called Wnt) in brain stem cells may be a critical key to developing therapies that would enable the restoration of damaged tissues.

The joint research, funded by the National Multiple Sclerosis Society and the UK MS Society as well as the National Institutes of Health and Howard Hughes Medical Institute, was conducted by scientists at the University of California San Francisco (UCSF) and University of Cambridge and was published today (01 July) in the journal Genes and Development.

Source: insciences.org

Broad researchers help develop method that enhances large-scale measurement of low abundance proteins.

Harbingers of disease come in several forms, but there is increasing interest in molecular signposts, particularly proteins, that can act as early warning signals for doctors and their patients. But before such protein “biomarkers” can be deployed in the clinic, they have to be identified in the laboratory and then repeatedly tested in hundreds, preferably thousands, of patient samples to assure that they are effective indicators of disease. It is a long and arduous path from the bench to the clinic, one that is made even more challenging by several key technological gaps in the large-scale analysis of proteins (known as “proteomics”).

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News), today announced that the Company will release certain preliminary financial results for the quarter ended June 30, 2009 at 8:00 AM Eastern on Wednesday, July 8, 2009. The Company will hold a conference call to discuss these preliminary financial results at 10:00 AM Eastern on Wednesday, July 8, 2009 which will be hosted by Edward Rubin and David Horin, Rodman & Renshaw Capital Group’s Chief Executive Officer and Chief Financial Officer, respectively.

Department of Education. And Down Will Come Baby. And Down Will Come Baby is a 17 minute video about the effects of exposure to alcohol and other drugs on the fetus during pregnancy. Accompanying the video is a Teachers Guide designed to promote a 15-20 minute discussion of the video.

The purpose of the video is to promote awareness of the problem among teenagers who are at risk for both unplanned pregnancy and substance use. This gripping film take a serious, no-holds-barred look at what happens when pregnant women use alcohol, tobacco and other drugs. The film includes an examination of prenatal drug and alcohol abuse, fetal alcohol syndrome, nicotine's effect on unborn babies, risks for AIDS, SIDS and FAS, drug effects at various stages of pregnancy, how drugs affect unborn babies and other relation social and emotional problems. Fetal Alcohol Syndrome (FAS) and a spectrum of associated disorders, sometimes called Fetal Alcohol Spectrum Disorders (FASD), is a permanent birth defect caused by maternal consumption of alcohol during pregnancy.

Nick gave for the Senate Committee on Homeland Security and Governmental Affairs about diabetes research

He Speaks Out to the Committee About Finding the Cure of Type 1 Diabetes in Capital Hill Washington DC on June 23, 2009

HE Talks about finding the cure of type 1 diabetes.

Source: Senate Committee on Homeland Security and Governmental Affairs, Bekah

"If It Feels Good Do It" : Using Neuromarketing to Go Beyond Click-Through: the Emerging Understanding of the Links Between Biometric Measures and Consumer Response to Media, presented by André Marquis.

How is biotech doing as a group?

The BTK index had a change of 3.25% last week, closing at 701.20, compared to the NASDAQ’s change of 0.59%, while the NBI was up 2.36%, closing at 751.52 The profitable biotechs trade at 18.3 times the FY09 consensus EPS estimates, vs. the historical mean of 44.6 times forward earnings. The PEG on FY09 earnings is 1.1, below the historical mean of 1.6 and well below the historical high of 2.9, while the group’s 2008-2011 CAGR is 16.7

The Samaveda (Sanskrit from sāman "melody" + veda "knowledge" ), is second (in the usual order) of the four Vedas, the ancient core Hindu scriptures. Its earliest parts are believed to date from 1000 BC and it ranks next in sanctity and liturgical importance to the Rigveda. It consists of a collection of hymns, portions of hymns, and detached verses, all but 75 taken from the Rigveda, to be sung, using specifically indicated melodies called Samagana, by Udgatar priests at sacrifices in which the juice of the Soma plant, clarified and mixed with milk and other ingredients, is offered in libation to various deities.

The verses have been transposed and re-arranged, without reference to their original order, to suit the rituals in which they were to be employed. There are frequent variations from the text of the Rigveda that are in some cases glosses but in others offer an older pronunciation than that of the Rigveda. When sung the verses are further altered by prolongation, repetition and insertion of stray syllables, as well as various modulations, rests and other modifications prescribed in the song-books.

The Secret team has created a visualization tool, "The Secret to You", which you can download for free and play every day.
http://rich.thesgrprogram.com

"The Secret to You" has been especially created to harness all the power of The Secret to transform your life into happiness, prosperity, health, love and joy.

To experience maximum power from the visualization tool, read the words and feel them with all your heart.

From all at The Secret, we celebrate you, we give thanks for you and we wish you a life beyond your wildest dreams.

Cooley's Anemia, also known as Thalassemia, is a fatal genetic blood disorder which affects people of Mediterranean descent. Today, in order to survive, children must receive blood transfusions every two weeks and receive painful drug injections via an infusion pump every night of their lives.

In its major form Cooley's Anemia is fatal. Over two million people in the United States are carriers of the minor form and do not even know it. The bad news is that these people are at risk in passing along the major form if they have children. The good news is that finally a cure is in sight.

Posted by Edyta Zielinska, TheScientist.com

Experts in nanomedicine are questioning the credentials of a researcher who has portrayed himself as an expert in the fledgling field, even starting a professional society and procuring a post as editor of the journal Nanomedicine.

Indeed, an investigation of his credentials reveals that he claimed to hold a directorship of a non-existent program, co-authored only two original papers in nanomedicine (one of which, a co-author says, he contributed to only editorially), and was accused of mismanaging the professional society to the point that some board members resigned and began a new professional group.

In a phase III study of patients with progressive well-differentiated pancreatic islet cell tumors, treatment with the tyrosine kinase inhibitor sunitinib significantly prolonged progression-free survival with “acceptable” safety.

“This important finding opens possibilities for future treatment of pancreatic islet cell tumors,” Dr. Eric Raymond, from Hospital Beaujon, Clichy, France and colleagues conclude in an abstract released today at the European Society for Medical Oncology’s (ESMO) 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain.

At a press event in London on Wednesday, HTC unveiled its latest Google Android device, the HTC Hero, featuring a new user interface called HTC Sense.

Sergey Brin and Steve Horowitz discuss the availability of the SDK, that it will be open source in the future, and demo applications on the Android platform.

The real beauty of the smartphone lies beneath the surface. The new Sense UI allows users to customize the device to their needs and give them more access to the information they want at a glance through widgets, customized profiles, and consolidated views of all communication with a contact, whether it be e-mail, text or multimedia message, Facebook status updates, or photos. In addition, HTC said that all of its future devices will use Sense UI.